 (INNO), Quote.Headers.trade-ideas

Technology

Healthcare

Consumer Cyclical

Other

Communication Services

Industrials

Financial Services

Fund invests primarily in equity securities, principally common stocks, of companies selected based on their potential for growth tied to disruptive innovation. The Fund defines disruptive innovation as the development of new products, services, technologies and/or other advancements that could disrupt and displace existing businesses and business models over time.

Lam Research Corp

Nvidia Corp.

Alphabet Holding Company Inc.

Servicenow, Inc

Asml Holding N.V. Ordinary Shares

Progressive Corp.

Danaher Corp.

Advanced Micro Devices Inc.

Texas Instruments Inc

Cadence Design Systems Inc.

Harbor Disruptive Innovation ETF

cannabis money, cannabis earnings, marjijuana money,

Cannabis

Earnings

News

AMZN

CSE:INNO

INNO

INNPF

Innocan Pharma&#39;s Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance.

CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark

Cannabis oil regulation(Shutterstock)(18)

Health Care

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA, for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.

This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain

Cannabis_stocks_rise-1 copy

Earnings Beats

Innocan Pharma&#39;s 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision.

534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations

Harbor ETF Trust Harbor Disruptive Innovation ETF

INNOSPEC ORD

INNOVATIVE CLIMATIC TECH by Innovative Climatic Technologies Corp

INNOVATIVE INDUSTRIAL PPTY ORD

INNOVATIVE INTERNATIONAL ACQUISITION CORP UNIT 1 COM & 1/2 WT EXP

Inno Holdings Inc

INNOCAN PHARMA CORP. by Innocan Pharma Corp.

InnoCan Pharma Corp

INNOCARE PHARMA LTD by INNOCARE PHARMA LTD.

InnoCare Pharma Ltd

InnoTech Corp

Innodata Inc

INNOLOG HOLDINGS CORP by Innolog Holdings Corp.

Innolog Holdings Corp

Innospec Inc

Innotech Corp

InnovAge Holding Corp

InnovaCom Inc

InnovaQor Inc

Innovaro Inc

Innovate Corp

Innovation Beverage Group Ltd

INNOVATION PHARMACEUTICAL by Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Inc

INNOVATION1 BIOTECH IN by Innovation1 Biotech Inc.

Innovation1 Biotech Inc

INNOVATIVE DESIGNS INC by Innovative Designs, Inc.

Innovative Designs Inc

Innovative Eyewear Inc

INNOVATIVE FOOD HLDGS INC by Innovative Food Holdings, Inc.

Innovative Food Holdings Inc

INNOVATIVE HLDGS ALL INC by Innovative Holdings Alliance,Inc.

Innovative Holdings Alliance Inc

Innovative Industrial Properties, Inc. Common Stock

Innovative Industrial Properties Inc

Innovative Industrial Properties, Inc. 9.00% Series A Cumulative Redeemable Preferred Stock

INNOVATIVE MEDTECH INC by Innovative MedTech Inc.

Innovative MedTech Inc

INNOVATIVE PYMNT SOLUTION by Innovative Payment Solutions, Inc.

Innovative Payment Solutions Inc

Innovative Solutions and Support, Inc. - Common Stock

Innovative Solutions and Support Inc

Innovator 20 Year Treasury Bond 5 Floor ETF - July

Innovator 20 Year Treasury Bond 9 Buffer ETF - July

Innovator Deepwater Frontier Tech ETF

Innovator Defined Wealth Shield ETF

Innovator ETFs Trust DOUBLE STACKER 9 BUFFER ETF JANUARY

Innovator ETFs Trust DOUBLE STACKER ETF -JAN

Innovator ETFs Trust Innovator Buffer Step-Up Strategy ETF

Innovator ETFs Trust Innovator Equity Defined Protection ETF - 1 Yr August

Innovator ETFs Trust Innovator Equity Defined Protection ETF - 2 Yr to January 2026

Innovator ETFs Trust Innovator Equity Defined Protection ETF - 2 Yr to July 2025

Innovator ETFs Trust Innovator Equity Managed Floor ETF

Innovator ETFs Trust Innovator Gradient Tactical Rotation Strategy ETF

Innovator ETFs Trust Innovator Growth Accelerated Plus ETF - January

Innovator ETFs Trust Innovator Growth-100 Power Buffer ETF - August

Innovator ETFs Trust Innovator Hedged TSLA Strategy ETF

Innovator ETFs Trust Innovator International Developed Power Buffer ETF August

Innovator ETFs Trust Innovator International Developed Power Buffer ETF December

Innovator ETFs Trust Innovator International Developed Power Buffer ETF February

Innovator ETFs Trust Innovator International Developed Power Buffer ETF March

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

Innovator ETFs Trust Innovator International Developed Power Buffer ETF September

Innovator ETFs Trust Innovator Laddered Allocation Buffer ETF

Innovator ETFs Trust Innovator Nasdaq-100 Managed Floor ETF

Innovator ETFs Trust Innovator Power Buffer Step-Up Strategy ETF

Innovator ETFs Trust Innovator Premium Income 10 Barrier ETF - April

Innovator ETFs Trust Innovator Premium Income 10 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 10 Barrier ETF - July

Innovator ETFs Trust Innovator Premium Income 10 Barrier ETF - October

Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - April

Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - January

Innovator ETFs Trust Innovator Premium Income 15 Buffer ETF - October

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - April

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - July

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - October

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - April

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - July

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - October

Innovator ETFs Trust Innovator Premium Income 40 Barrier ETF - April

Innovator ETFs Trust Innovator Premium Income 40 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 40 Barrier ETF - July

Innovator ETFs Trust Innovator Premium Income 40 Barrier ETF - October

Innovator ETFs Trust Innovator Premium Income 9 Buffer ETF - January

Innovator ETFs Trust Innovator Premium Income 9 Buffer ETF - October

Innovator ETFs Trust Innovator U.S. Equity 10 Buffer ETF - Quarterly

Innovator ETFs Trust Innovator U.S. Equity 5 to 15 Buffer ETF - Quarterly

Innovator ETFs Trust Innovator U.S. Equity Accelerated 9 Buffer ETF - January

Innovator ETFs Trust Innovator U.S. Equity Accelerated ETF - January

Innovator ETFs Trust Innovator U.S. Equity Accelerated ETF - Quarterly

Innovator ETFs Trust Innovator U.S. Equity Accelerated Plus ETF - January

Innovator ETFs Trust Innovator US Small Cap Power Buffer ETF - August

Innovator ETFs Trust Innovator Uncapped Accelerated U.S. Equity ETF

Innovator ETFs Trust TRIPLE STACKER ETF JAN

Innovator Emerging Markets Power Buffer ETF - October

Innovator Emerging Markets Power Buffer ETF April

Innovator Emerging Markets Power Buffer ETF January

Innovator Emerging Markets Power Buffer ETF July

Innovator Growth Accelerated ETF - Quarterly

Innovator Growth Accelerated Plus ETF - April

Innovator Growth Accelerated Plus ETF - July

Innovator Growth Accelerated Plus ETF - October

Innovator Growth-100 Power Buffer ETF - April

Innovator Growth-100 Power Buffer ETF - January

Innovator Growth-100 Power Buffer ETF - July

Innovator Growth-100 Power Buffer ETF- October

Innovator Hedged Nasdaq-100 ETF

Innovator IBD 50 ETF

Many plan to work well into their 60s or even 70s, thinking they can compensate for years of undersaving. But according to recent surveys, retirement may come earlier than expected for many Americans – whether they're <a href="https://www.benzinga.com/personal-finance/24/05/38761475/retire-early-or-retire-rich-man-asks-whether-its-better-to-retire-at-40-with-125-000-a-year-or-a">ready for it or not.</a>
The average retirement age in the U.S. is about 62 years old, even though most workers expect to retire around 67. In fact, more than 56% of retirees left the workforce earlier than they planned, according to a Transamerica survey. So, what's causing this <a href="https://www.benzinga.com/personal-finance/24/09/40800774/gen-xs-looming-retirement-crisis-is-worse-than-they-realize-expert-compares-it-to-being-handed-a">gap between expectations and reality</a>?
Don' Miss:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>
Health is a big factor. Roughly 38% of early retirees say they had to stop working because of health issues or disabilities. This isn't always part of the plan, but sudden medical conditions or ongoing health problems can change things quickly. This is a reality many don't account for when imagining working into their late 60s or 70s.
Then there's the job market itself. Fourteen percent of those who retired early did so after being laid off; for many, finding another job isn't appealing or feasible. 
Trending: <a href="https://www.benzinga.com/money/charlie-munger-100k">Charlie Munger said if you want to be rich, &#8220;find a way to get your hands on $100,000&#8221; — here&#8217;s what he means.</a>
Companies downsize, industries change and job security becomes less certain as people age, making retirement sometimes <a href="https://www.benzinga.com/personal-finance/24/07/39892121/top-economist-debunks-myth-you-need-1-46-million-to-retire-argues-you-can-retire-comfortably-wit">less of a choice and more of a necessity</a>.
In addition to these reasons, life events – like family changes or unexpected financial shifts – can also force people to reconsider their plans. Some may find they've saved enough to retire early, but for most, it's often a mix of circumstance and necessity that leads them there.
Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a>
Financially, retiring earlier than planned can be a challenge. Many people end up dipping into their savings sooner than expected, which stretches their retirement funds thinner over a longer period. According to various reports, the average American retiree has around $269,078 saved for retirement, far below what's typically recommended. Financial planners suggest a target of around $572,000 and that gap can mean tough choices down the road.
Additionally, if people claim Social Security benefits before they hit their full retirement age – 67 for many – they'll see a permanent reduction in monthly benefits. Plus, if they retire before Medicare eligibility kicks in at 65, they may <a href="https://www.benzinga.com/personal-finance/24/08/40624190/aon-predicts-9-increase-in-employer-health-care-costs-for-2025-heres-whats-fueling-the-spike">face higher health care costs</a> or gaps in coverage.
Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a>
So, what does this all mean? Planning to work longer might not be the foolproof strategy some hope it will be. Between health issues, layoffs and other unexpected life events, early retirement happens to more people than you might think. And without enough savings, the <a href="https://www.benzinga.com/personal-finance/24/07/39866450/the-average-retiree-spends-over-52-000-a-year-and-75-of-that-goes-to-just-five-expenses-how-does">financial picture</a> can get complicated fast.&nbsp;
While everyone's situation is different, having a backup plan and saving more now might be the safest bet for those who want more control when they retire. It's always smart to reassess your retirement plan and <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">consulting with a financial advisor</a> can give you a clearer picture of where you stand. They can help you adjust your savings strategy, review your investment options and ensure you're prepared for any surprises that could force early retirement. 
Read Next:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>

Personal Finance

Most People Expect To Retire at 67, But 56% Retire Sooner – Can You Guess the Actual Average Retirement Age?

W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) has outperformed the market over the past 5 years by 15.22% on an annualized basis producing an average annual return of 29.13%. Currently, W.W. Grainger has a market capitalization of $50.23 billion. 
Buying $1000 In GWW: If an investor had bought $1000 of GWW stock 5 years ago, it would be worth $3,534.58 today based on a price of $1028.81 for GWW at the time of writing.
<h3>W.W. Grainger's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726860639_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In W.W. Grainger 5 Years Ago Would Be Worth Today

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.58% on an annualized basis producing an average annual return of 14.06%. Currently, Centene has a market capitalization of $39.78 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 20 years ago, it would be worth $1,562.27 today based on a price of $75.63 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726860634_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,600 Today

Lennar Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/len#NYSE">LEN</a>) reported third-quarter fiscal 2024 results, wherein its earnings and revenues surpassed the Zacks Consensus Estimate.
On a year-over-year basis, revenues increased, given the company&#39;s emphasis on maintaining a steady production rate to drive sales momentum. Lennar strategically utilized pricing, incentives, marketing expenditure and dynamic pricing insights to ensure steady sales volume despite fluctuations in interest rates.
However, earnings fell by a cent from the year-ago period. LEN&#39;s stock plunged 2.4% in the after-hours trading session on Sept. 19. Investors&#39; sentiments might have been hurt by lower earnings and gross margin in the fiscal third quarter, as well as tepid fiscal fourth-quarter guidance.
<h2>Quarterly Numbers</h2>
LEN reported adjusted earnings per share (excluding mark-to-market gains on technology investments and one-time items in its Multifamily segment) of $3.90, which topped the Zacks Consensus Estimate of $3.62 by 7.7%. The metric, however, slipped 0.3% year over year from $3.91 per share.
<div class="chart_embed">
<h3>Lennar Corporation Price, Consensus and EPS Surprise</h3>
<img alt="Lennar Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/fa/1726841318.png" style="height:265px; width:589px" title="" />
Lennar Corporation price-consensus-eps-surprise-chart | Lennar Corporation Quote
Revenues of $9.42 billion topped the Zacks Consensus Estimate of $9.29 billion by 1.4% and rose 7.9% year over year from $8.73 billion.
</div>
<h2>Segment Details</h2>
Homebuilding: Revenues of the segment totaled $9.05 billion, up 8.7% from the prior-year quarter. Under the Homebuilding umbrella, home sales contributed $9.02 billion to total revenues, up 8.8% from a year ago.
Land sales accounted for $19.5 million, down from $20.4 million in the prior-year quarter. The Other homebuilding unit contributed $8.6 million to homebuilding revenues, down from $12.3 million a year ago.
Home deliveries for the reported quarter improved 16% from the year-ago level to 21,516 units. The reported figure was better than our projection of 20,598 units for the quarter. The average sales price&nbsp;of homes delivered was $422,000, down 5.8% from the year-ago figure due to pricing to market through an increased use of incentives and product mix. Our model had predicted ASP to be $432,910 for the fiscal third quarter.
New orders rose 5% from the year-ago quarter to 20,587 homes. However, the potential value of net orders fell 0.9% year over year to $8.56 billion.
Backlog at the fiscal third-quarter end declined 20.5% from the year-ago quarter to 16,944 homes. Potential housing revenues from backlog decreased 21.4% year over year to $7.75 billion.
The gross margin on home sales was 22.5% for the quarter, down 190 basis points (bps). Notably, the reported figure came below our projection of 23% for the quarter. The decline was mainly due to decreased revenues per square foot and increased land costs year over year.
SG&amp;A expenses &mdash; as a percentage of home sales &mdash; decreased 30 bps to 6.7% due to a decrease in broker commissions and benefits of LEN&#39;s technology efforts.
Financial Services: The segment&#39;s revenues increased year over year to $273.3 million from $266.2 million for the reported quarter. Operating earnings for the quarter increased to $144.4 million from $149 million a year ago.
Lennar Multi-Family: Revenues of $93.4 million in the segment were down from $137.4 million in the prior-year quarter. The segment registered operating earnings of $78.9 million for the quarter against a loss of $8.7 million a year ago.
Lennar Other: The segment&#39;s revenues totaled $3.6 million, significantly down from $7.4 million a year ago. Its operating earnings were $20.1 million for the quarter against a loss of $26.2 million a year ago.
<h2>Financials</h2>
At the fiscal third-quarter end, Lennar had homebuilding cash and cash equivalents of $4.04 billion, down from $6.27 billion at the end of fiscal 2023. LEN has no outstanding borrowings under the $2.2 billion revolving credit facility, thereby providing $6.2 billion of liquidity.
The total homebuilding debt was $2.26 billion as of the fiscal third-quarter end, down from $2.82 billion at the fiscal 2023-end. Homebuilding debt to capital at the fiscal third-quarter end was 7.6%, down from 9.6% at the fiscal 2023-end.
LEN repurchased 3.4 million shares for $519 million in the fiscal third quarter.
<h2>Guidance</h2>
For fourth-quarter fiscal 2024, the company expects deliveries within 22,500-23,000 homes, depicting a fall from 23,795 homes delivered in the year-ago period. The company expects the ASP of the delivered units to be nearly $425,000, down from an ASP of $441,000 reported a year ago.
The gross margin on home sales is expected to be flat year over year. SG&amp;A expenses, as a percentage of home sales, are likely to be in the range of 6.7-6.8% for the quarter. In the prior year, gross margin was 24.2%, and SG&amp;A was 6.6%.
New orders are likely to be within 19,000-19,300 units, up from 17,366 homes reported a year ago.
Financial Services operating earnings are expected to be around $140 million, down from $168 million a year ago.
<h2>LEN&#39;s Zacks Rank &amp; Stocks to Consider</h2>
Lennar currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the same space are M/I Homes, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mho#NYSE">MHO</a>), Meritage Homes Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mth#NYSE">MTH</a>)&nbsp;and PulteGroup, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phm#NYSE">PHM</a>). Each stock presently carries a Zacks Rank #2 (Buy).
M/I Homes is a Columbus, OH-based homebuilder that engages in the construction and sale of single-family residential homes.
MHO&#39;s EPS estimates for 2024 have increased to $19.76 from $19.58 over the past 30 days. The company&#39;s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average being 4.8%. MHO&#39;s earnings are expected to rise 21.9% year over year in 2024.
Meritage Homes is a Scottsdale, AZ-based company that designs and builds single-family attached and detached homes.
MTH&#39;s EPS estimates for 2024 have increased to $21.09 from $20.33 over the past 60 days. The company&#39;s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 21.5%. MTH&#39;s earnings are expected to rise 5.8% year over year in 2024.
PulteGroup is an Atlanta, GA-based homebuilder engaged in homebuilding and financial services businesses.
PHM&#39;s EPS estimates for 2024 have increased to $13.36 from $12.85 over the past 60 days. The company&#39;s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 10%. PHM&#39;s earnings are expected to rise 14% year over year in 2024.
<a href="https://www.zacks.com/stock/news/2339343/lennar-q3-earnings-revenues-beat-stock-down-on-tepid-q4-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-2339343">To read this article on Zacks.com click here.</a>

Guidance

Markets

Analyst Ratings

Lennar Q3 Earnings & Revenues Beat, Stock Down on Tepid Q4 View

Onconetix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares are trading lower by 29.9% to 8 cents Friday after the company announced a <a href="https://www.benzinga.com/pressreleases/24/09/g40961281/onconetix-inc-announces-1-for-40-reverse-stock-split-and-results-of-the-annual-meeting-of-stockhol">1-for-40 reverse stock split</a>. The company announced that its stockholders approved all proposals at the 2024 annual meeting held on September 5.
What Happened: These approvals included the election of Timothy Ramdeen and Ajit Singh as directors for a three-year term, amendments to the company's 2022 Equity Incentive Plan to increase the number of shares issuable, and authorization for a reverse stock split at a ratio ranging from 1-for-30 to 1-for-60. 
The board chose a 1-for-40 ratio, effective September 24, to help the company meet Nasdaq's minimum bid price requirement.
What Else: Other approved measures included the issuance of shares related to the conversion of Series A and Series B Preferred Stock, a private placement, and the assumption of stock options from Proteomedix AG. Stockholders also ratified EisnerAmper LLP as the company's independent auditor for 2024.
The reverse stock split will reduce Onconetix&#8217;s outstanding shares from around 30.2 million to approximately 755,000.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40960886/palantir-dell-to-join-s-p-500-friday-heres-how-tesla-stock-has-performed-since-its-add">Palantir, Dell To Join S&amp;P 500 Friday: Here&#8217;s How Tesla Stock Has Performed Since Its Addition In 2020</a>
<h2 class="wp-block-heading">Is ONCO A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ONCO">Onconetix</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Onconetix does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 8.33%, you'll need to buy a share of AMEN Properties by the Sep. 30, 2024. Once done, you can expect to receive a nominal payout of $10.0 on Oct. 7, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/ONCO">Onconetix</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ONCO has a 52-week high of $0.54 and a 52-week low of $0.08.

ONCO

Why Onconetix (ONCO) Shares Are Down 27%

INTC

QCOM

Wall Street Journal Reported Qualcomm Approached Intel About A Takeover

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
The <a target="_blank" href="https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices" rel="noreferrer noopener">complaint</a> accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of prescriptions in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38564498/federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-" rel="noreferrer noopener">Federal Trade Commission Targets &#8216;Junk Patent Listings&#8217; For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca</a>.
The FTC claims that the PBMs abused their market power to inflate insulin prices by promoting a rebate system with drug manufacturers.
This system led to the exclusion of lower-priced insulin from formularies, further driving up the cost for vulnerable patients.
The result is higher out-of-pocket expenses for those needing essential diabetes medication.
For example, the list price of Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Humalog rose dramatically from $21 in 1999 to over $274 in 2017.
Despite the availability of lower-priced alternatives, PBMs favored higher-priced drugs due to the lucrative rebates they provided.
The FTC is also examining the role of drug manufacturers, including Eli Lilly, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), in driving up insulin prices, signaling potential further action against these companies.
The rebate-driven system excluded lower-priced insulins and allowed the Big Three PBMs to keep significant revenue in the form of rebates and fees, a strategy that hurt patients while benefiting the PBMs financially.
Vulnerable patients, such as those with high deductibles or coinsurance, bore the brunt of these inflated costs, paying more for their insulin than the overall net cost to insurers.
Price Action: At last check Friday, CVS stock was down 1.61% at $57.49, UNH stock was down 0.29% at $575.39, and CI stock was up 0.07% at $357.52.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40961594/mullen-automotive-gears-up-210m-ev-deal-in-dubai-delivers-first-units-to-volt-mobility" target="_blank" rel="noreferrer noopener">Mullen Automotive Gears Up $210M EV Deal In Dubai – Delivers First Units To Volt Mobility</a>.</li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Large Cap

Legal

General

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) announced that the FDA issued a complete response letter&nbsp;to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis.
Shares of the company were down 6.1% on Sept. 19 following the announcement of the news.
Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach&#39;s ability to empty its contents. The FDA has not approved any effective medicine for treating gastroparesis in more than 40 years.
Year to date, shares of Vanda have increased 10.2% compared with the industry&#39;s rise of 0.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4a/78570.jpg?v=840412258" />
Image Source: Zacks Investment Research
<h2>More on FDA&#39;s CRL for VNDA&#39;s Tradipitant</h2>
Per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease.
Also, per management, the FDA delayed its decision by more than 185 days and failed to meet the requirements specified by the Food Drug and Cosmetic Act (FDCA).
Notably, the FDCA requires that the FDA review an NDA and provide either an approval or a possible hearing within 180 days of the filing. The FDA failed to do either.
Per the company, it had time and again asked the FDA to hold an advisory committee meeting to discuss the NDA for tradipitant while the regulatory body declined.
Several patients treated with tradipitant have now filed a Citizen Petition pleading with the regulatory body to approve tradipitant for the treatment of gastroparesis.
<h2>VNDA&#39;s Development Plans for Tradipitant</h2>
Despite the FDA declining to approve tradipitant for treating symptoms in gastroparesis, the company will continue to pursue the marketing approval for tradipitant in the given indication.
Apart from gastroparesis, VNDA is also developing tradipitant for preventing vomiting induced by motion sickness.
In May 2024, the company announced positive data from a second phase III study that investigated tradipitant for preventing vomiting induced by motion sickness.
Vanda plans to submit an NDA for tradipitant to the FDA for the treatment of motion sickness later in 2024.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Vanda currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.84 to $3.63. Earnings per share estimates for 2025 have improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 3.5%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.7%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.33 to 28 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 48.9%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2339326/vnda-stock-down-as-fda-rejects-nda-for-tradipitant-in-gastroparesis?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2339326">To read this article on Zacks.com click here.</a>

Biotech

Penny Stocks

Small Cap

Management

FULC

ILMN

KRYS

VNDA

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

Sable Offshore Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) shares are trading lower by 21.3%% to $22.26 Friday afternoon after the company announced a $150 million private placement of <a href="https://www.benzinga.com/pressreleases/24/09/b40954952/sable-offshore-corp-announces-150-million-private-placement-of-shares-and-update-on-warrant-exerci">7.50 million shares</a>.
The private placement is set to close on September 23, pending standard conditions. The funds will be used for capital expenditures, working capital, and general corporate purposes.
Additionally, as of September 18, 2024, Sable has raised $64.8 million from the exercise of warrants, issuing 5.6 million shares. These funds will also be used for similar corporate purposes. 
TD Cowen, Jefferies and Intrepid Partners are handling the placement.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/09/40962983/wall-street-falls-on-triple-witching-day-feds-waller-pushes-gold-to-fresh-record-highs-fedex-plu">Wall Street Falls On Triple Witching Day, Fed&#8217;s Waller Pushes Gold To Fresh Record Highs, FedEx Plummets: What&#8217;s Driving Markets Friday?</a>
<h2 class="wp-block-heading">How To Buy SOC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Sable Offshore&#8217;s case, it is in the Energy sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOC has a 52-week high of $28.67 and a 52-week low of $10.11.

Why Sable Offshore (SOC) Stock Is Getting Hammered

A win by former President Donald Trump in the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election </a>could raise concerns about conflicts of interest related to his ownership of a media company.
What Happened: Trump i<a href="https://www.benzinga.com/news/24/09/40939390/trump-media-technology-group-stock-slides-as-lockup-expiration-looms-whats-going-on">s the co-founder</a> of Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), a media company that owns the Truth Social platform and other media assets.
While investors are worried that Trump<a href="https://www.benzinga.com/general/social-media/24/09/40860859/trump-media-technology-shares-surge-former-president-says-hes-not-selling-or-leaving-truth-s"> might sell his shares</a> after a lockup expiration, ethics watchdogs are concerned about who could be buying the shares ahead of the 2024 election or if Trump returns to the White House.
According to a report from Politico, purchasers of the stock could include foreign actors or people seeking corporate interests.
"It's a huge potential conflict of interest," Project on Government Oversight Director of Government Affairs Dylan Hedtler-Gaudette said, as <a href="https://www.politico.com/news/2024/09/19/trump-social-media-stake-ethics-00180038">reported</a> by Politico.
Hedtler-Gaudette said ethics concerns over businesses connected to Trump are not new, but having a public company and being president could amplify the concerns.
Trump's media company has set up rules that he<a href="https://www.benzinga.com/m-a/23/08/33878846/trump-to-maintain-control-of-media-company-if-he-sells-majority-goes-to-jail-or-becomes-president"> will still maintain control</a> of the company if he goes to prison or becomes president. Trump will also keep control if he sells his stock, as long as he keeps his special shares that come with voter control.
Ownership of a media company could have ethics watchdogs on alert if Trump does return to the White House.
"This is a potentially dangerous situation," former White House ethics lawyer Richard Painter told Politico. "The government shouldn't be controlling the press (and) that's where we are in social media."
Trump recently said he created Trump Media after being banned from other social media platforms. The venture arose after he began using traditional press releases to engage with his supporters, a strategy that quickly proved successful.
One potential concern is if Trump opts to bypass traditional media press releases or mainstream outlets, choosing instead to communicate exclusively through Truth Social or other companies he owns.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092024">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While most presidents haven't owned stocks while in office or put their investments into blind trusts to avoid conflicts of interest, it doesn't appear Trump will be changing his tune about DJT shares anytime soon.
Trump's ownership of hotels were previously involved in ethics concerns due to how government officials were billed for their use while Trump was in office.
According to the report, those seeking favors from Trump or hoping for him to make decisions or publicly support certain positions may perceive increased chances of success if they purchase shares in his company. Members of Congress <a href="https://www.benzinga.com/general/social-media/24/08/40475137/djt-stock-hits-new-lows-since-trump-media-companys-public-debut-heres-how-much-marjorie-tayl">who own DJT shares</a> could also see their prominence rise if Trump returns to the White House.
With Trump's continued ownership of Trump Media &amp; Technology Group, there remains multiple ethics concerns at play if he returns to the White House. The president owning a media company that could profit from his exclusive access, coupled with individuals publicly buying shares in Trump&#8217;s company to demonstrate loyalty, could emerge as significant issues moving forward.
DJT Price Action: Trump Media &amp; Technology shares are down 6.7% to $13.70 on Friday. The stock hit new post-SPAC merger lows of $13.50 earlier in the day. The stock is down 19% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/09/40943414/donald-trump-can-cash-out-his-trump-media-technology-stock-keep-company-control-heres-how-ma">Donald Trump Can Cash Out His Trump Media &amp; Technology Stock, Keep Company Control: Here&#8217;s How Many Shares He Owns</a></li>
</ul>
Photo: Shutterstock

Politics

Movers

Trump's Stake In Media Group Raises Ethics Concerns Ahead Of 2024 Election: Report

Shares of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) are down 1.91% to $239.38 Friday afternoon, reversing gains from Thursday's trading session, amid this week&#8217;s unexpected 50-basis-point interest rate cut by the Federal Reserve and <a href="https://www.benzinga.com/markets/equities/24/09/40962983/wall-street-falls-on-triple-witching-day-feds-waller-pushes-gold-to-fresh-record-highs-fedex-plu">overall market weakness</a>.
The decline comes as broader concerns about economic growth and demand pressures begin to weigh on the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle (EV)</a> maker's outlook.
Initial Rally On Lower Rates: Tesla stock surged on Thursday following the Federal Reserve&#8217;s decision to cut interest rates by 50 basis points at the September Federal Open Market Committee (FOMC) meeting, reducing the federal funds rate to a range of 4.75% to 5%. This larger-than-expected rate cut was welcomed by growth-oriented companies like Tesla, which stand to benefit from lower borrowing costs.
The Fed's updated Dot Plot signaled the possibility of additional rate cuts in 2024 and 2025, leading to optimism that cheaper financing would spur demand for capital-intensive goods such as electric vehicles. Lower interest rates also typically make it easier for consumers to finance big-ticket purchases like cars, further boosting demand for Tesla's vehicles.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944143/wall-street-breaks-records-chipmakers-rally-tesla-hits-2-month-high-as-fed-cut-drives-risk">Wall Street Breaks Records Thursday, Chipmakers Rally, Tesla Hits 2-Month High As Fed Cut Drives Risk-On Mode: What&#8217;s Driving Markets Thursday?</a>
Despite Thursday&#8217;s positive market reaction, Tesla shares dropped on Friday as investors digested the broader implications of the Federal Reserve's latest projections. Several key factors contributed to the decline:
Weaker Economic Growth Outlook: The Federal Reserve revised its GDP growth forecast for 2024 down from 2.1% to 2.0%, signaling slower economic activity ahead. Tesla, which relies on strong consumer demand for its premium electric vehicles, is vulnerable to any signs of economic weakening. A slower growth environment could weigh on consumer spending and potentially reduce demand for discretionary items like cars.
Higher Unemployment Forecast: The Fed also revised its unemployment projections upward, now expecting a 4.4% jobless rate in 2024, up from the previous 4.0%. Rising unemployment could further dampen demand for Tesla's vehicles, as higher joblessness tends to constrain household budgets, particularly for large purchases like electric cars.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40961610/fedex-falls-15-after-earnings-miss-bearish-signals-raise-red-flags-for-investors">FedEx Falls 15% After Earnings Miss, Bearish Signals Raise Red Flags For Investors</a>
Concerns Over Tesla's Margins: With a weakening economy, Tesla might need to lower vehicle prices or offer more incentives to maintain demand, potentially squeezing profit margins.
The company has already engaged in several rounds of price cuts throughout 2024 to stay competitive in the growing EV market, which has seen increased competition from legacy automakers and new entrants.
Inflation and Fed's Confidence in Rate Cuts: While the Fed's downward revisions of inflation forecasts for 2024 and 2025 signal a softer inflationary environment, they may also hint at a prolonged period of disinflation.
 A prolonged slowdown in inflation and economic activity could hinder Tesla's growth prospects, particularly in key markets like the U.S. and Europe, where consumer spending may decelerate.
Valuation Concerns Amid Volatility: Tesla, which is traditionally valued at high multiples compared to earnings, faces heightened volatility during periods of economic uncertainty. 
The combination of a slower economy, higher unemployment, and potential margin pressures raises questions about the sustainability of Tesla's lofty valuation. This could prompt profit-taking among investors after Thursday's rally.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40960886/palantir-dell-to-join-s-p-500-friday-heres-how-tesla-stock-has-performed-since-its-add">Palantir, Dell To Join S&amp;P 500 Friday: Here&#8217;s How Tesla Stock Has Performed Since Its Addition In 2020</a>
<h2 class="wp-block-heading">How To Buy TSLA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tesla&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TSLA has a 52-week high of $271.00 and a 52-week low of $138.80.

TSLA

What's Going On With Tesla Stock Today

Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) reportedly ruled out taking an equity stake in Woodside Energy Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDS#NYSE">WDS</a>) <a href="https://www.benzinga.com//node/39879353">upcoming acquisition of Driftwood LNG in Louisiana.</a>
Colin Parfitt, head of midstream operations, told Reuters that Chevron can effectively monetize its U.S. gas without converting it to LNG.
The decision reflects the company&#8217;s earlier choice to bypass investment in U.S. LNG plant construction and sell its gas directly to the market instead.
In July 2023, Chevron executives said in an interview that the company is confident in its &#8216;buy-rather-than-build&#8217; strategy, which an S&amp;P Global <a target="_blank" href="https://www.spglobal.com/commodityinsights/en/market-insights/latest-news/natural-gas/072023-interview-chevron-prefers-buying-us-lng-to-building-export-projects" rel="noreferrer noopener">report </a>highlighted.
During the interview, the company&#8217;s executives stated that Chevron&#8217;s U.S. LNG offtake contracts support its goal of increasing international sales of Permian Basin production, while the company will primarily leave U.S. midstream infrastructure development to third parties to focus on upstream and downstream investments.
In 2022, Chevron&nbsp;U.S.A. entered into long-term <a href="https://lngir.cheniere.com/news-events/press-releases/detail/253/cheniere-and-chevron-sign-long-term-lng-sale-and-purchase">LNG </a>sale and purchase agreements with Cheniere Energy. Notably, given the current interest rate environment, it&#8217;s interesting that Chevron chose not to invest in the construction of a U.S. LNG plant.
Recently, the Federal Reserve decided to reduce interest rates by 50 basis points leading to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40937291/bank-stocks-hit-inflection-point-after-feds-50-basis-point-cut-analyst-reveal-top-p" target="_blank" rel="noreferrer noopener">surge in optimism across major sectors</a>.
Further into the future, the Dot Plot signals the fed funds rate will drop to between 3.25% and 3.5% by the end of 2025, implying an additional 100 basis points of cuts. By the end of 2026 and the newly introduced projections for 2027, <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead" target="_blank" rel="noreferrer noopener">interest rates are expected to fall to 2.9%</a>.
It remains uncertain whether the company will alter its stance after future rate reductions as it wants the best use of its capital.
This week, Chevron Shipping Company, in partnership with Wärtsilä, disclosed that it will convert engines on six&nbsp;liquefied natural gas&nbsp;(LNG) carriers from dual-fuel to spark gas operation to cut methane&nbsp;emissions <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40941443/chevron-takes-steps-to-reduce-methane-emissions-from-lng-carriers" rel="noreferrer noopener">and support its carbon reduction goals</a>.
Investors can gain exposure to the Chevron via&nbsp;E.A. Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;SPDR Select Sector Fund – Energy Select Sector&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: CVX shares are up 0.13% at $145.18 at the last check Friday.
Photo by Jonathan Weiss on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40920735/chevron-slams-bidens-lng-export-pause-touts-natural-gas-for-ai-growth-report" target="_blank" rel="noreferrer noopener">Chevron Slams Biden&#8217;s LNG Export Pause, Touts Natural Gas For A.I. Growth: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of A.I. tools and was reviewed and published by Benzinga editors.

Equities

Media

DRLL

Chevron Prioritizes Gas Sales Over LNG Plant Investment: Report

Earlier on Friday, &nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40961934/novo-nordisk-stock-declines-after-headline-results-from-mid-stage-study-of-monlunabant-in-obese-p" rel="noreferrer noopener">inverse agonist</a>.
After 16 weeks of treatment, people treated with a once-daily 10 mg dose of monlunabant achieved a weight loss of 7.1 kg compared to a reduction of 0.7 kg with a placebo.
Probably, the investors are reacting to the limited additional weight loss seen at higher doses.
In March, Novo Nordisk <a target="_blank" href="https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P5-Obesity-Care.pdf" rel="noreferrer noopener">shared</a> monlunabant update during its Capital Markets Day 2024.
In Phase 1, monlunabant produced a statistically significant mean weight loss of 3.5 kg (3.3%) compared to 0.6 kg (0.5%) with placebo at day 28.
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) and Skye Bioscience Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>)&nbsp;stocks plunged in reaction to the data.
All three companies are developing weight loss drugs that employ a mechanism of action, peripheral CB1 inhibition.
Corbus Pharmaceuticals&#8217; investigational CRB-913, also a CB1 inverse agonist, is in the preclinical phase. Human <a target="_blank" href="https://www.corbuspharma.com/our-pipeline" rel="noreferrer noopener">trials</a> are expected to start in the first quarter of 2025.
Analyst reactions:
<ul>
<li>Wedbush maintains Corbus Pharmaceuticals with an Outperform rating and lowered the price <a href="https://www.benzinga.com/quote/CRBP/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $85 to $51</a>.</li>
<li>B. Riley Securities maintains Corbus with a Buy and lowered the price target from $85 to $40.</li>
</ul>
Skye is conducting a Phase 2 trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1.
This study is also assessing the combination of nimacimab and Novo Nordisk&#8217;s Wegovy (semaglutide). Skye <a target="_blank" href="https://ir.skyebioscience.com/company-information" rel="noreferrer noopener">expects</a> interim and topline data from its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40503382/skye-bioscience-launches-phase-2-cbeyond-clinical-trial-of-its-differentiated-cb1-inhibitor-nimaci" rel="noreferrer noopener">Phase 2 study in 2025</a>.
Jefferies analyst notes that while expectations for Corbus&#8217; asset have been tempered, key uncertainties persist, making it difficult to draw firm conclusions. This is particularly true as Novo Nordisk advances its obesity candidate. Additional insights from long-term open-label extension data, expected in late October, may provide more clarity.
Price Action: SKYE stock is down 41% at $3.24, and CRBP stock is down 59.4% at $21.00 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40963255/johnson-johnsons-rybrevant-scores-third-fda-approval-of-2024-for-certain-type-of-inoperable-lung-" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients</a>.</li>
</ul>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Overview

(INNO), Quote.Headers.trade-ideas